Von Willebrand's disease

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 525-542

  Ewenstein, Bruce M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bleeding disorder; Desmopressin; Factor VIII; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; GENE PRODUCT; GLYCOPROTEIN; VON WILLEBRAND FACTOR;

CRYOPRECIPITATE; DISEASE CLASSIFICATION; ELECTROPHORESIS; HEMOSTASIS; HUMAN; LABORATORY DIAGNOSIS; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW; VON WILLEBRAND DISEASE;

COMBINED MODALITY THERAPY; DEAMINO ARGININE VASOPRESSIN; DIAGNOSIS, DIFFERENTIAL; FACTOR VIII; HUMANS; MUTATION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0031047775     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.525     Document Type: Review

References (120)

1. Rodeghiero F, Castaman G, Dini E. 1987. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69:454-59
2. Sadler JE, Matsushita T, Dong Z, et al. 1995. Molecular mechanism and classification of von Willebrand disease. Thromb. Haemost. 74:161-66
3. von Willebrand EA. 1926. Hereditär pseudohämofili. Fin. Läkäresallsk. Handl. 67:7-12
4. von Willebrand EA. 1931. Über hereditäre Pseudohämophilie. Acta. Med. Scand, 76: 521-50
5. Minot GR. 1928. A familial hemorrhagic condition associated with prolongation of the bleeding time. Am. J. Med. Sci. 175: 301-6
6. Buckman TE. 1928. Atypical pathologic hemorrhage in early life. Am. J. Med. Sci. 175:307-12
7. Bouma BN, Wiegerinck Y, Sixma JJ, et al. 1972. Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in von Willebrand's disease. Nature New Biol. 236:104-6
8. Holmberg L, Nilsson IM. 1972. Genetic variants of von Willebrand's disease. Br. Med. J. 3:317-20
9. Hoyer LW, Shainoff JR. 1980. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 55:1056-59
10. Ruggeri ZM, Pareti FI, Mannucci PM, et al. 1980. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N. Engl. J. Med. 302:1047-51
11. Titani K, Kumar S, Takio K, et al. 1986. Amino acid sequence of human von Willebrand factor. Biochemistry 25:3171-84
12. Bonthron DT, Handin RI, Kaufman RJ, et al. 1986. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature 324:270-73
13. Bonthron DT, Orr EC, Mitsock LM, et al. 1986. Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic Acids Res. 14:7125-27
14. Shelton-Inloes BB, Broze GRJ, Miletich JP, Sadler JE. 1987. Evolution of human von Willebrand factor: cDNA sequence polymorphisms, repeated domains, and relationship to von Willebrand antigen II. Biochem. Biophys. Res. Commun. 144: 657-65
15. Shelton-Inloes BB, Titani K, Sadler E. 1986. cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms. Biochemistry 25:3164-71
16. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. 1986. Full length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 5:1839-47
17. Sadler JE. 1994. A revised classification of von Willebrand disease. Thromb. Haemost. 71:520-25
18. Larrieu MJ, Caen JP, Meyer DO, et al. 1968. Congenital bleeding disorders with long bleeding time and normal platelet count. II. von Willebrand's disease (report of thirty-seven patients). Am. J. Med. 45: 354-72
19. Silwer J, Nilsson IM. 1964. On a Swedish family with 51 members affected by von Willebrand's disease. Acta Med. Scand. 175:627-43
20. Holmberg L, Nilsson IM. 1992. von Willebrand's disease. Eur. J. Haematol. 48:127-41
21. Foster PA. 1994. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. Thromb. Haemost. 71: 784-90
22. Fressinaud E, Meyer D. 1993. International survey of patients with von Willebrand disease and angiodysplasia. Thromb. Haemost. 70:546-50
23. Ginsburg D, Sadler JE. 1993. von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb. Haemost. 69:177-84
24. Mancuso DJ, Tuley EA, Westfield LA, et al. 1989. Structure of the gene for human von Willebrand factor. J. Biol. Chem. 264: 19514-27
25. Ginsburg D, Handin RI, Bonthron DT, et al. 1985. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 228:1401-6
26. Jaffe EA, Hoyer LW, Nachman RL. 1973. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J. Clin. Invest. 52:2757-64
27. Nachman R, Levine R, Jaffe EA. 1977. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J. Clin. Invest. 60:914-21
28. Sadler JE. 1991. von Willebrand factor. J. Biol. Chem. 266:22777-80
29. Wagner DD. 1990. Cell biology of von Willebrand factor. Annu. Rev. Cell. Biol. 6:217-46
30. Eikenboom JCJ, Reitsma PH, Peerlinck KMJ, Briët E. 1993. Recessive inheritance of von Willebrand's disease type I. Lancet 341:982-86
31. Zhang ZP, Falk G, Blombäck M, et al. 1992. Identification of a new nonsense mutation in the von Willebrand factor gene in patients with von Willebrand disease type III. Hum. Mol. Genet. 1:61-62
32. Zhang ZP, Lindstedt M, Falk G, et al. 1992. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am. J. Hum. Genet. 51:850-58
33. Zhang ZP, Falk G, Blombäck M, et al. 1992. A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients. Hum. Mol. Genet. 1:767-68
34. Weiss HJ, Ball AP, Mannucci PM. 1982. Incidence of severe von Willebrand's disease. N. Engl. J. Med. 307:127 (Lett.)
35. Peake IR, Liddell MB, Moodie P, et al. 1990. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood 75:654-61
36. Nichols WC, Lyons SE, Harrison JS, et al. 1991. Severe von Willebrand disease due to a defect at the level of von Willebrand factor mRNA expression: detection by exonic PCR-restriction fragment length polymorphism analysis. Proc. Natl. Acad. Sci. USA 88:3857-61
37. Weiss HJ, Pietu G, Rabinowitz R, et al. 1983. Heterogenous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/ von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease. J. Lab. Clin. Med. 101: 411-25
38. Mannucci PM, Lombardi R, Bader R, et al. 1985. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 66:796-802
39. Rodeghiero F, Castaman G, DiCona E, et al. 1988. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intraplatelet von Willebrand factor. Eur. J. Haematol. 40:163-67
40. Orstavik KH, Magnus P, Reisner H, et al. 1985. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am. J. Hum. Genet. 37:89-101
41. Gill JC, Endres-Brooks J, Bauer PJ, et al. 1987. The effect of ABO blood group on the diagnosis of von Willebrand disease, Blood 69:1691-95
42. Rogers JS II, Shane SR, Jencks FS. 1982. Factor VIII activity and thyroid function. Ann. Intern. Med. 97:713-16
43. Dalton RG, Dewar MS, Savidge GF, et al. 1987. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1:1007-9
44. Strauss HS, Diamond LK. 1963. Elevation of factor VIII (antihemophilic factor) during pregnancy in normal persons and in a patient with von Willebrand's disease. N. Engl. J. Med. 269:1251-52
45. Leone G, Moneta E, Paparatti G, Boni P. 1975. von Willebrand's disease in pregnancy. N. Engl. J. Med. 293:456 (Lett.)
46. Verweij CL, Hart M, Pannekoek H. 1987. Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J. 6:2885-90
47. Wise RJ, Pittman DD, Handin RI, et al. 1988. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell 52: 229-36
48. Wagner DD, Fay PJ, Sporn LA, et al. 1987. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc. Natl. Acad. Sci. USA 84: 1955-59
49. Mayadas TN, Wagner DD. 1992. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc. Natl. Acad. Sci. USA 89:3531-35
50. Levine JD, Harlan JM, Harker LA, et al. 1982. Thrombin-mediated release of factor VIII antigen from human umbilical vein endothelial cells in culture. Blood 60:531-34
51. 2+ associated with von Willebrand factor release in endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J. Clin. Invest. 79:600-8
52. Datta YH, Romano M, Jacobson BC, et al. 1995. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation 92:3304-11
53. Gaucher C, Diéval J, Mazurier C. 1994. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 84:1024-30
54. 53a. Schneppenheim R, Thomas KB, Krey S, et al. 1995. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum. Genet. 95: 681-86
55. Ginsburg D, Bowie EJW. 1992. Molecular genetics of von Willebrand disease. Blood 79:2507-19
56. Jakway JL. 1992. Acquired von Willebrand's disease. Hematol. Oncol. Clin. North Am. 6:1409-19
57. Meyer D, Frommel D, Larrieu MJ, Zimmerman TS. 1979. Selective absence of large forms of factor VIII/von Willebrand factor in acquired von Willebrand's syndrome. Response to transfusion. Blood 54: 600-6
58. Mannucci PM, Lombardi R, Bader R, et al. 1984. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 64:614-21
59. Joist JH, Cowan JF, Zimmerman TS. 1978. Acquired von Willebrand's disease. Evidence for a quantitative and qualitative factor VIII disorder. N. Engl. J. Med. 298: 988-91
60. Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. 1989. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J. Biol. Chem. 264: 17361-67
61. Fujimura Y, Titani K, Holland LZ, et al. 1986. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J. Biol. Chem. 261:381-85
62. Cruz MA, Handin RI, Wise RJ. 1993. The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX: the role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein. J. Biol. Chem. 268: 21238-45
63. Denis C, Baruch D, Kielty CM, et al. 1993. Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. Arterioscl. Thromb. 13:398-406
64. Rabinowitz I, Tuley EA, Mancuso DJ, et al. 1992. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc. Natl. Acad. Sci. USA 89:9846-49
65. Kaufman RJ. 1992. Biological regulation of factor VIII activity. Annu. Rev. Med. 43:325-99
66. Foster PA, Fulcher CA, Marti T, et al. 1987. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J. Biol. Chem. 262:8443-46
67. Jorieux S, Tuley EA, Gaucher C, et al. 1992. The mutation Arg(53)-Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Blood 79:563-67
68. Lind SE. 1984. Prolonged bleeding time. Am. J. Med. 77:305-12
69. Burns ER, Lawrence C. 1989. Bleeding time. A guide to its diagnostic and clinical utility. Arch. Pathol. Lab. Med. 113: 1219-24
70. Rodgers RP, Levin J. 1990. A critical reappraisal of the bleeding time. Semin. Thromb. Hemost. 16:1-20
71. Kumar R, Ansell JE, Canoso RT, Deykin D. 1978. Clinical trials of a new bleeding time device. Am. J. Clin. Pathol. 70:642-45
72. Ivy AC, Shapiro PF, Melnick G. 1935. The bleeding time in jaundice. Surg. Gynecol. Obstet. 66:781
73. Lamme S, Wallmark A, Holmberg L, et al. 1985. The use of monoclonal antibodies in measuring factor VIII/von Willebrand factor. Scand. J. Clin. Lab. Invest. 15:17-26
74. Zimmerman TS, Ratnoff OD, Powell AE. 1971. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and an acquired circulating anticoagulant against antihemophlic factor. J. Clin. Invest. 50:244-54
75. Ruggeri ZM, Zimmerman TS. 1980. Variant von Willegrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J. Clin. Invest. 65:1318-25
76. Chow R, Savidge GF. 1985. Enzyme linked antibody system for the visualization of FVIII multimers. Thromb. Haemost. 54: 75a (Abstr.)
77. Mannucci PM, Abildgaard CF, Gralnick HR, et al. 1985. Multicenter comparison of von Willebrand factor multimer sizing techniques. Report of the factor VIII and von Willebrand factor subcommittee. Thromb. Haemost. 54:873-77
78. Abildgaard CF, Suzuki Z, Harrison J, et al. 1980. Serial studies in von Willebrand's disease: variability versus "variants." Blood 56:712-16
79. Weiss HJ. 1975. Abnormalities of factor VIII and platelet aggregation-use of ristocetin in diagnosing the von Willebrand syndrome. Blood 45:403-12
80. Weiss HJ, Meyer D, Rabinowitz R, et al. 1982. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular weight multimers. N Engl. J. Med. 306:326-33
81. Macfarlane DE, Stibbe K, Kirby EP, et al. 1975. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb. Diath. Haemorrh. 34:306-8
82. Weiss HJ, Rogers J, Brand H. 1973. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J. Clin. Invest. 52: 2697-707
83. Italian Working Group. 1977. Spectrum of von Willebrand's disease: a study of 100 cases. Br. J. Haematol. 35:101-12
84. Weiss HJ. 1974. Relation of von Willebrand factor to bleeding time. N. Engl. J. Med. 291:420
85. Blatt PM, Brinkhous KM, Culp HR, et al. 1976. Antihemophilic factor concentrates therapy in von Willebrand's disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA 236:2770-72
86. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1977. DDAVP: a new pharmacological approach to the management of haemophilia and von Willebrand's diease. Lancet 1:869-72
87. Mannucci PM, Lombardi R, Castaman G, et al. 1988. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 71:65-70
88. Rodeghiero F, Castaman G, diBona E, Ruggeri M. 1989. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 74:1997-2000
89. Lethagen S, Harris AS, Nilsson IM. 1990. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I. Blut 60:187-91
90. Lusher JM. 1994. Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease. Haemostasis 24:276-84
91. Mannucci PM, Lusher JM. 1989. Desmopressin and thrombosis. Lancet 2:675-77
92. Holmberg L, Nilsson IM, Borge L, et al. 1983. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type HB von Willebrand's disease. N. Engl. J. Med. 309:816-21
93. Castaman G, Rodeghiero F. 1996. Desmopressin and type IIB von Willebrand disease. Haemophilia 2:73-77
94. Mannucci PM. 1994. Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease. Haemostasis 24:285-88
95. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. 1992. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 79:3130-37
96. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. 1992. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox. Sang. 62: 193-99
97. Mannucci PM, Chediak J, Byrnes J, et al. 1996. A high purity factor VIII concentrate in the treatment of von Willebrand's disease. Haemophilia 2:111-15
98. 96a. Hanna WT, Bona RD, Zimmerman CE, et al. 1994. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb. Haemost. 71:173-79
99. Fukui H, Nishino M, Terada S, et al. 1988. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease. Blut 56:171-78
100. Schimpf K, Mannucci PM, Kreutz W, et al. 1987. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. N. Engl. J. Med. 316:918-22
101. Czapek EE, Gadarowski JJ, Ontiveros JD, Pedraza JL. 1988. Humate P for treatment of von Willebrand disease. Blood 72:1100 (Lett.)
102. Scharrer I, Vigh T, Aygören-Pürsün E. 1994. Experience with Haemate P in von Willebrand's disease in adults. Haemostasis 24:298-303
103. Kreuz W, Mentzer D, Becker S, et al. 1994. Haemate P in children with von Willebrand's disease. Haemostasis 24:304-10
104. Goudemand J, Mazurier C, Marey A, et al. 1992. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Br. J. Haematol. 80:214-21
105. Alperin JB. 1982. Estrogens and surgery in women with von Willebrand's disease. Am. J. Med. 73:367-71
106. Hoyer LW, Rizza CR, Tuddenham EGD, et al. 1983. von Willebrand factor multimer patterns in von Willebrand's disease. Br. J. Haematol. 55:493-507
107. Ruggeri ZM, Nilsson IM, Lombardi R, et al. 1982. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J. Clin. Invest. 70:1124-27
108. Kinoshita S, Harrison J, Lazerton J, Abildgaard CF. 1984. A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID). Blood 63: 1369-71
109. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. 1986. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J. Clin. Invest. 77:947-51
110. Mannucci PM, Lombardi R, Federici AB, et al. 1986. A new variant of type II von Willebrand disease with aberrant multimeric structure of plasma but not platelet von Willebrand factor (type IIF). Blood 68:269-74
111. Gralnick HR, Williams SB, McKeown LP, et al. 1987. A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure. Am. J. Hematol. 24: 259-66
112. Federici AB, Mannucci PM, Lombardi R, et al. 1989. Type IIH von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity. Am. J. Hematol. 32:287-93
113. Castaman G, Rodeghiero F, Lattuada A, Mannucci PM. 1992. A new variant of von Willebrand disease (type III) with a normal degree of proteolytic cleavage of von Willebrand factor. Thromb. Res. 65:343-51
114. Howard MA, Salem HH, Thomas BK, et al. 1982. Variant von Willebrand's disase type B revisited. Blood 60:1420-28
115. Ciavarella G, Ciavarella N, Antoncecchi S, et al. 1985. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC). Blood 66:1423-29
116. Lopez-Fernandez MF, Gonzalez-Boullosa R, Blanco-Lopez MJ, et al. 1991. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID). Am. J. Hematol. 36:163-70
117. Weiss HJ, Sussman II. 1986. A new von Willebrand factor variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing all vWF multimers. Blood 68:149-56
118. Holmberg L, Dent JA, Schneppenheim R, et al. 1993. von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. J. Clin. Invest. 91:2169-77
119. Mazurier C, Dieval J, Jorieux S, et al. 1990. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF: characterization of abnormal vWF/ FVIII interaction. Blood 75:20-26
120. Zimmerman TS, Ruggeri ZM. 1982. von Willebrand's disease. Prog. Hemost. Thromb. 6:203-36